Debjit Chattopadhyay (Guggenheim) — Analyst Ratings, Accuracy & Track Record

Q: How accurate are Debjit Chattopadhyay's stock ratings?

About 48% of Debjit's ratings were profitable over a one-year hold, with an average return of +2.6% per rating, measured by 13Foresight from historical prices.

Q: How is Debjit ranked?

Debjit Chattopadhyay is ranked #2236 on 13Foresight, scored on hit rate, average return versus the market, and number of calls.

Analyst Tracker/Debjit Chattopadhyay

GUGG

Debjit Chattopadhyay

Guggenheim

Wall Street Analyst

★★☆☆☆

#2236

on 13Foresight · ranked by our own returns

48%

Success Rate

+2.5%

Average Return

28 of 58 calls profitable · -2331.4% vs benchmark

Time Frame ⓘ

1 Yr 2 Yr 3 Yr 5 Yr

Compare To ⓘ

📈 Across the calls we could measure, roughly 48% of Debjit Chattopadhyay's ratings turned a profit when each position was held for 1 year — averaging +2.5% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

54 Buy 6 Hold 0 Sell

Debjit's Stock Coverage 55 ratings · 2026-07-14

Company	Date	Position	Consensus ⓘ	Price Target ⓘ	1-Yr Return
TSE:MSCL Satellos Bioscience	Jul 09, 2026	BUY	Strong Buy +155.4% avg upside 6 analysts	$32.60 141.01% Upside	·
EWTX Edgewise Therapeutics	Jul 06, 2026	BUY	Strong Buy +8.7% avg upside 14 analysts	$51.00 12.30% Upside	+11.3%
NGNE Neurogene	Jun 30, 2026	BUY	Strong Buy +27.0% avg upside 23 analysts	$69.00 74.16% Upside	·
SPRB Spruce Biosciences	Jun 16, 2026	BUY	Strong Buy +104.7% avg upside 14 analysts	$123.00 145.61% Upside	+5.7%
RZLT Rezolute	Jun 15, 2026	BUY	Strong Buy +124.1% avg upside 13 analysts	$11.00 131.65% Upside	+9.7%
NTLA Intellia Therapeutics	Jun 10, 2026	HOLD	Buy +193.2% avg upside 37 analysts	—	+16.5%
PASG Passage Bio	Jun 10, 2026	HOLD	Buy +290.6% avg upside 14 analysts	—	·
BNTC Benitec Biopharma	Jun 10, 2026	HOLD	Strong Buy +103.6% avg upside 13 analysts	—	·
PEPG PepGen Inc.	Jun 08, 2026	BUY	Strong Buy +344.0% avg upside 9 analysts	$7.00 199.09% Upside	·
TRDA Entrada Therapeutics Inc	Jun 05, 2026	BUY	Strong Buy +214.6% avg upside 10 analysts	$17.00 145.69% Upside	+3.6%
IRD Opus Genetics	Jun 04, 2026	BUY	Strong Buy +172.0% avg upside 24 analysts	$16.00 308.08% Upside	-15.5%
VYGR Voyager Therapeutics	Jun 02, 2026	BUY	Strong Buy +336.0% avg upside 23 analysts	$22.00 539.52% Upside	-8.1%
DTIL Precision BioSciences	May 28, 2026	BUY	Strong Buy +171.8% avg upside 12 analysts	$19.00 116.92% Upside	+26.6%
RARE Ultragenyx Pharmaceutical	May 08, 2026	BUY	Strong Buy +101.1% avg upside 36 analysts	$43.00 27.19% Upside	+29.5%
NAMS NewAmsterdam Pharma Company	May 07, 2026	BUY	Strong Buy +38.0% avg upside 18 analysts	$45.00 27.64% Upside	+1.2%
KRYS Krystal Biotech	May 04, 2026	BUY	Strong Buy -31.4% avg upside 19 analysts	$284.00 22.28% Downside	+27.5%
SLDB Solid Biosciences	Mar 20, 2026	BUY	Strong Buy +61.2% avg upside 23 analysts	$26.00 149.55% Upside	+43.5%
MAZE Maze Therapeutics, Inc.	Mar 04, 2026	BUY	Strong Buy +112.8% avg upside 12 analysts	$58.00 89.78% Upside	-34.2%
PHVS Pharvaris	Dec 03, 2025	BUY	Strong Buy +29.3% avg upside 14 analysts	$39.00 11.18% Upside	+19.4%
LXEO Lexeo Therapeutics, Inc.	Oct 15, 2025	BUY	Strong Buy +314.3% avg upside 11 analysts	$30.00 522.42% Upside	-41.0%
QURE uniQure	Sep 24, 2025	BUY	Strong Buy +43.1% avg upside 29 analysts	$95.00 122.78% Upside	-4.9%
IONS Ionis Pharmaceuticals	Sep 22, 2025	BUY	Strong Buy +39.5% avg upside 43 analysts	$92.00 58.03% Upside	-5.1%
SRPT Sarepta Therapeutics	Sep 15, 2025	BUY	Buy +216.9% avg upside 49 analysts	$22.00 16.19% Upside	+8.5%
PRME Prime Medicine, Inc.	Aug 13, 2025	BUY	Strong Buy +174.6% avg upside 16 analysts	$5.00 32.37% Upside	+4.7%
BMRN BioMarin Pharmaceutical	Aug 06, 2025	BUY	Strong Buy +59.7% avg upside 52 analysts	$106.00 79.26% Upside	-2.5%
VRTX Vertex Pharmaceuticals	Aug 06, 2025	BUY	Strong Buy -8.0% avg upside 61 analysts	$546.00 12.47% Upside	+25.9%
BEAM Beam Therapeutics	May 07, 2025	BUY	Strong Buy +63.7% avg upside 25 analysts	$55.00 68.28% Upside	+93.9%
DYN Dyne Therapeutics	Aug 14, 2024	BUY	Strong Buy +62.5% avg upside 30 analysts	$50.00 113.59% Upside	-71.5%
CRSP Crispr Therapeutics AG	Jun 28, 2024	HOLD	Buy +46.6% avg upside 41 analysts	—	-12.1%
ALNY Alnylam Pharma	Jun 27, 2022	HOLD	Strong Buy +19.8% avg upside 51 analysts	—	+28.9%
TSHA Taysha Gene Therapies	Apr 05, 2022	BUY	Strong Buy +138.9% avg upside 21 analysts	$24.00 278.53% Upside	-89.7%
EDIT Editas Medicine	Mar 17, 2021	HOLD	Buy +329.5% avg upside 33 analysts	—	-62.9%
SGMOQ Sangamo Therapeutics	Jan 06, 2021	HOLD	Buy +11775.2% avg upside 16 analysts	$16.00 15900.07% Upside	·
STRO Sutro Biopharma	Sep 03, 2020	BUY	Strong Buy +35.8% avg upside 20 analysts	$17.00 42.74% Downside	+67.2%
WVE Wave Life Sciences	Sep 01, 2020	BUY	Strong Buy +264.1% avg upside 28 analysts	$20.00 220.10% Upside	-47.6%
STOK Stoke Therapeutics	Aug 31, 2020	BUY	Strong Buy +28.6% avg upside 18 analysts	$30.00 4.42% Downside	-10.9%
CH:MOLN Molecular Partners AG	Aug 28, 2020	BUY	Strong Buy +551.8% avg upside 5 analysts	$25.00 674.08% Upside	·
LKFT Lakefront Biotherapeutics	Aug 24, 2020	HOLD	Buy +253.6% avg upside 24 analysts	$123.00 306.32% Upside	·
QTTB Q32 Bio	Aug 11, 2020	BUY	Buy +247.7% avg upside 24 analysts	$30.00 167.70% Upside	-39.4%
TECX Tectonic Therapeutic	Aug 10, 2020	HOLD	Strong Buy +64.1% avg upside 24 analysts	$13.00 62.25% Downside	-66.1%
AUTL Autolus Therapeutics	Aug 07, 2020	BUY	Strong Buy +600.4% avg upside 16 analysts	$24.00 1390.71% Upside	·
ZYME Zymeworks	Aug 06, 2020	BUY	Strong Buy +26.9% avg upside 25 analysts	$54.00 108.59% Upside	+12.3%
BCYC Bicycle Therapeutics	Aug 06, 2020	BUY	Strong Buy +456.6% avg upside 20 analysts	$25.00 466.99% Upside	+83.9%
ALLO Allogene Therapeutics	Aug 06, 2020	BUY	Strong Buy +682.6% avg upside 28 analysts	$49.00 2350.09% Upside	-37.1%
FATE Fate Therapeutics	Aug 06, 2020	BUY	Strong Buy +283.8% avg upside 31 analysts	$42.00 1254.81% Upside	+185.5%
MGNX MacroGenics	Jul 31, 2020	BUY	Buy +299.4% avg upside 25 analysts	$40.00 823.72% Upside	-1.7%
NKTR Nektar Therapeutics	May 12, 2020	HOLD	Strong Buy +3.7% avg upside 25 analysts	$26.00 63.09% Downside	-14.5%
SMMT Summit Therapeutics	Dec 18, 2019	BUY	Strong Buy +91.6% avg upside 27 analysts	$2.00 86.83% Downside	+278.2%
AGIO Agios Pharma	Aug 01, 2017	HOLD	Buy +50.0% avg upside 29 analysts	—	+47.9%
CORT Corcept Therapeutics	Dec 20, 2016	SELL	Buy -50.3% avg upside 15 analysts	$7.00 92.45% Downside	-89.7%
DARE Daré Bioscience	Oct 20, 2016	HOLD	Strong Buy +544.5% avg upside 14 analysts	$1.50 25.81% Downside	-66.6%
NEO NeoGenomics	Oct 26, 2015	BUY	Strong Buy +11.6% avg upside 17 analysts	$10.00 29.21% Downside	+4.1%
PTCT PTC Therapeutics	Oct 16, 2015	HOLD	Buy -4.6% avg upside 29 analysts	$63.00 25.71% Downside	-62.4%
AWHL Aspira Women's Health	Aug 16, 2015	BUY	Buy +1309.8% avg upside 6 analysts	$4.00 900.03% Upside	-35.1%
ARCT Arcturus Therapeutics	Aug 14, 2015	BUY	Buy +330.3% avg upside 36 analysts	$16.00 129.59% Upside	-42.5%

🔒 50 more ratings — with price targets, crowd consensus and our measured returns.

Free account unlocks every analyst's full coverage table.

Debjit Chattopadhyay — Frequently Asked Questions

How accurate are Debjit Chattopadhyay's stock ratings?

Based on the calls 13Foresight could measure, about 48% of Debjit's ratings were profitable over a one-year hold, with an average return of +2.6% per rating, or -2331.2% versus the S&P 500. We score every analyst the same way, from historical prices.

How is Debjit ranked on 13Foresight?

Debjit Chattopadhyay is currently ranked #2236 with a 2-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.

Which stocks does Debjit cover?

Debjit most recently has ratings on TSE:MSCL, EWTX, NGNE, SPRB, RZLT, NTLA, PASG, BNTC, PEPG, TRDA, IRD, VYGR and 43 more. See the full coverage table above for positions, price targets and our measured returns.

Where can I see other analyst ratings?

Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.

Rating Distribution

Welcome to 13Foresight!